(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings - 2Top 15 Web-based Entertainment Stages for Individual Marking
- 3Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- 4'Crammed into a cell with vermin at New Year'
- 5Israeli military says it hit dozens of military facilities in Tehran
- New Year's superstitions: Eating 12 grapes, avoiding laundry and other rituals that are said to bring good fortune
- Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- Hanwha Ocean secures orders worth $866m for five vessels
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Astronomers spot white dwarf star creating a colorful shockwave
- The Best Cell phone Brands for Tech Aficionados
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- Astounding Treehouses All over the Planet
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
